Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | CPA1 | P15085 | 5/20 | 0.49 |
| ▸ | CPA3 | P15088 | 3/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | CPB1 | P15086 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19483359 | 0.86 | CYP1A2 (0.55) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL19483390 | 0.86 | CYP1A2 (0.55) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL1709335 | 0.84 | ESR1 (0.47) | CYP1A2PPARGEPHX2MAPT | |
| SCHEMBL1709306 | 0.81 | HTR2A (0.47) | CYP1A2CPA1 | |
| SCHEMBL265514 | 0.81 | CYP1A2 (0.83) | CYP1A2PPARGCPA1CPA3FOLH1 | |
| SCHEMBL265063 | 0.81 | CYP1A2 (0.83) | CYP1A2PPARGCPA1CPA3FOLH1 | |
| SCHEMBL4886609 | 0.81 | CYP1A2 (0.69) | CYP1A2PPARGCPA1CPA3FOLH1 | |
| SCHEMBL491524 | 0.81 | CYP1A2 (0.83) | CYP1A2PPARGCPA1CPA3FOLH1 | |
| SCHEMBL1703264 | 0.80 | MAPT (0.49) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL1706267 | 0.80 | MAPT (0.49) | CYP1A2CPA1CPA3FOLH1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | CYP1A2 3371/4885PPARG 773/4885CPA1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.